XML 58 R50.htm IDEA: XBRL DOCUMENT v3.25.3
Revenue and Accounts Receivable Credit Concentration - Additional Information (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Disaggregation Of Revenue [Line Items]            
Sources of revenue, description       We derive our revenue from two sources: (i) Diagnostic Tests, providing lung diagnostic testing services for healthcare providers associated with our five blood-based tests and (ii) Development Services, providing diagnostic testing services to biopharmaceutical, life sciences, and diagnostic companies.    
Revenue recognized       $ 1,700    
Deferred revenue $ 2,773 $ 2,773   2,773   $ 678
Accounts receivable, net of allowance for credit losses 35 $ 35   $ 35   481
Revenue | Minimum | Customer Concentration Risk | Medicare            
Disaggregation Of Revenue [Line Items]            
Concentration risk, percentage   30.00% 40.00% 34.00% 40.00%  
Development Services            
Disaggregation Of Revenue [Line Items]            
Deferred revenue 2,400 $ 2,400   $ 2,400    
Non-refundable, up-front payment 3,000          
Accounts receivable, net of allowance for credit losses 3,000 3,000   3,000    
Up Front Cash Payments            
Disaggregation Of Revenue [Line Items]            
Deferred revenue 3,800 3,800   3,800    
Other Long-term Liabilities            
Disaggregation Of Revenue [Line Items]            
Non-current deferred revenue $ 100 $ 100   $ 100   $ 100